Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Bioavailability of Subcutaneous Lirentelimab in Healthy Volunteers
NCT04324268Phase 1Completed
- Sponsor
- Allakos Inc.
- Start
- Mar 2020
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lirentelimab in eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), eosinophilic esophagitis (EoE) and 3 more (10 arms), sponsored by Allakos Inc. Primary endpoints: Safety and tolerability of lirentelimab (AK002) and Pharmacokinetics, including bioavailability. Started Mar 2020; status: completed.
02
Drugs
lirentelimab
03
Conditions
eosinophilic gastritis (EG)eosinophilic duodenitis (EoD)eosinophilic esophagitis (EoE)chronic spontaneous urticaria (CSU)atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04324268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04324268.